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Abstract
Background: Genotype-phenotype association studies are typically based upon polymorphisms or haplotypes 
comprised of multiple polymorphisms within a single gene. It has been proposed that combinations of 
polymorphisms in distinct genes, which functionally impact the same phenotype, may have stronger phenotype 
associations than those within a single gene. We have tested this hypothesis using genes encoding components of the 
renin-angiotensin-aldosterone system and the high blood pressure phenotype.
Methods: Our analysis is based on 1379 participants of the cross-sectional SUNSET study randomly selected from the 
population register of Amsterdam. Each subject was genotyped for the angiotensinogen M235T, the angiotensin-
converting enzyme insertion/deletion and the angiotensin II type 1 receptor A1166C polymorphism. The phenotype 
high blood pressure was defined either as a categorical variable comparing hypertension versus normotension as in 
most previous studies or as a continuous variable using systolic, diastolic and mean blood pressure in a multiple 
regression analysis with gender, ethnicity, age, body-mass-index and antihypertensive medication as covariates.
Results: Genotype-phenotype relationships were explored for each polymorphism in isolation and for double and 
triple polymorphism combinations. At the single polymorphism level, only the A allele of the angiotensin II type 1 
receptor was associated with a high blood pressure phenotype. Using combinations of polymorphisms of two or all 
three genes did not yield stronger/more consistent associations.
Conclusions: We conclude that combinations of physiologically related polymorphisms of multiple genes, at least 
with regard to the renin-angiotensin-aldosterone system and the hypertensive phenotype, do not necessarily offer 
additional benefit in analyzing genotype/phenotype associations.
Background
Genotype-phenotype association studies have become
important tools to explore the pathophysiology of many
disease states. They are typically based on single poly-
morphisms in genes of interest. In some cases multiple
polymorphisms within a given gene exist in a fixed com-
bination, i.e. as haplotypes which may exhibit stronger/
more consistent associations with phenotypes than single
polymorphisms [1,2].
An expansion of this thought has been based upon
studies in the renin-angiotensin-aldosterone (RAAS) sys-
tem. The RAAS is an important regulator of cardiovascu-
lar function and blood pressure [3,4]. It consists mainly of
the angiotensin-converting enzyme (ACE) which metab-
olizes angiotensinogen (AGT) to form angiotensin II,
which can act angiotensin II type 1 receptors (AGTR1) to
mediate blood pressure elevations by mechanisms
including direct effects on vascular tone and indirect
effects via alterations of renal function. Thus, ACE, AGT
and AGTR1 act synergistically on the phenotype of blood
pressure. Each of the three corresponding genes has sev-
eral polymorphisms that can be associated with altered
expression or function of the corresponding gene prod-
uct. While each of these polymorphisms may potentially
affect the regulation of cardiovascular function by the
RAAS, most previous studies have focused on one poly-
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morphism in each of these genes, i.e. the single nucle-
otide polymorphism (SNP) M235T within exon 2 of the
AGT gene, an insertion/deletion (I/D) polymorphism
involving 287 bp in intron 16 of the ACE gene and the
A1166C SNP in the 3' untranslated part of the AGTR1
gene [5]. The 235T allele of the AGT gene is associated
with a stepwise increasing level of circulating angio-
tensinogen ("gene dose-response") [6,7]. The ACE I/D
polymorphism is strongly associated with the level of cir-
culating enzyme, with mean plasma ACE activities of DD
carriers being about twice those of II subjects and
heterozygotes having intermediate levels [8]. The direct
functional relevance of the 1166C allele of the AGTR1
gene is less clear, but it was shown recently to attenuate
the microRNA-155 binding leading to a decreased trans-
lation i.e. less receptor density in endothelial and vascular
smooth muscle cells [9] and this is associated with altered
serum aldosterone concentrations [10].
Accordingly, numerous studies have tested whether any
of the above three polymorphisms is associated with the
presence or severity of arterial hypertension (HT), almost
all of them using the categorical variable HT rather than
the underlying continuous variables of measured blood
pressure. However, the available data remain equivocal as
reports of associations have not been consistently con-
firmed, and even reports on inverse associations have
been published [5,11]. Retrospectively, this is not too sur-
prising as more recent genome wide analyses have not
implicated any of these three gene loci in arterial hyper-
tension [12-16]. Therefore, despite being an attractive
and pathophysiologically logical concept, the existence of
associations between polymorphisms in any of the three
main RAAS genes and HT remains unclear. Similarly dis-
appointing results of association studies have been found
between polymorphisms of components of the RAAS and
some phenotypes other than HT. However, for pheno-
types related to renal function a novel concept has been
proposed which has yielded stronger genotype-pheno-
type associations. This concept is based on the idea of
synergistic effects of RAAS components and proposes
that polymorphisms in each of the RAAS components,
which have minor effects in isolation, may have greater
effects when they occur concomitantly. Indeed a com-
bined analysis of polymorphisms in the ACE, AGT and
AGTR1 genes has shown stronger associations with prox-
imal renal sodium handling [17] or the development of
renal insufficiency [18] than any of the polymorphisms
studied in isolation. While haplotypes represent geneti-
cally fixed combinations of polymorphisms within a sin-
gle gene, this new concept is looking at functionally
related polymorphisms (FRPs) [19]. However, the validity
of this concept has not been tested against phenotypes
other than those directly related to renal function.
Against this background, we have explored whether the
FRP concept indeed provides stronger/more consistent
phenotype associations when applied to a different phe-
notype, i.e. HT. To increase the robustness of our
approach, the high blood pressure phenotype was charac-
terized concomitantly by the presence of HT or by sys-
tolic, diastolic or mean arterial pressure.
Methods
Study population
Our analysis is based on data obtained from the SUNSET
study (Surinamese in The Netherlands: Study on Ethnic-
ity and Health). In 1975, almost half the population of the
former Dutch colony Surinam migrated to the Nether-
lands. Approximately 80% of these immigrants are black
("Creoles", a mix of African, European and other ethnic
groups) or South Asian ("Hindustanis", originally from
the Indian sub-continent). SUNSET is based on a random
sample of 2975 individuals, aged 35-60 years, drawn from
the Amsterdam population register, as previously
described [20]. For further detailed description of the
study population, sampling procedure and determination
of ethnicity see also [21-23]. Following approval of the
study protocol by the Medical Ethical Committee of the
Academic Medical Center of the University of Amster-
dam, all participants gave informed written consent. Sub-
jects, who could not unequivocally be assigned to one of
the three ethnic groups, who did not undergo a blood
pressure measurement or who could not be genotyped
were excluded from the present study, leaving a total of
1379 persons for our present analysis although not all
variables could be documented for each of these subjects
[23].
Measurements
Blood pressure was measured in the morning on the right
arm in a seated position with a validated, automated, osc-
illometric, digital device (OMRON M-4, Omron Health-
care, Kyoto, Japan) by trained staff using appropriate cuff
sizes. Two readings were taken after the subject had emp-
tied the bladder and had been seated for at least 5 min;
the mean of the two readings was used in the analyses
[21]. In line with our previous genotype/phenotype asso-
ciation studies [23], we operationally defined the high
blood pressure phenotype as either the binary/categorical
variable HT or the linear variables systolic blood pressure
(SBP), diastolic blood pressure (DBP) and mean arterial
pressure (MAP). HT was operationally defined as having
a measured SBP >140 mmHg and/or a DBP >90 mmHg
and/or taking antihypertensive drugs. All other subjects
were assumed to have normal blood pressure.
Genotyping
DNA was isolated from whole blood using an Autopure
LS (Gentra Systems, Minneapolis, MN, USA). The AGTHahntow et al. BMC Cardiovascular Disorders 2010, 10:23
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M235T (rs699), ACE I/D (rs4340) and AGTR1 A1166C
(rs5186) polymorphisms were genotyped as previously
described [24].
Data analysis
Allele frequency was calculated in Haploview version
3.11 [25]. FRP analysis was performed with PHASE ver-
sion 2.1 analogous to the analysis of haplotypes [26,27],
which generates two FRPs per person. For FRP analysis
w e  u s e d  d o u b l e  a n d  t r i p l e  c o m b i n a t i o n s  o f  t h e  RA A S
components.
Data on continuous variables are shown as means ± SD
or as parameter estimates with 95% confidence intervals.
Categorical variables such as the prevalence of alleles and
FRPs as well as the prevalence of HT are reported as pro-
portions (%). Differences in prevalence of HT between
groups defined by genotype were tested using Fisher's
exact test (Table 1). Multiple linear regression analysis,
adjusted for gender, ethnicity, age, body-mass-index
(BMI) and the presence of concomitant antihypertensive
medication was used to study the association between
SBP, DBP and MAP on the one and single polymorphisms
or FRPs on the other hand (Table 2). Differences between
groups are given as mean parameter estimate with 95%
confidence intervals. For the AGT and ACE genes, the M
and I alleles, respectively, were defined as the reference
group as they should if anything associate with normo-
tension because of their association with lower expres-
sion [6-8]. Due to limited functional information there is
no clear biological way to define which of the AGTR1
gene alleles should be associated with normotension and
hence be seen as the reference allele; as our initial analysis
pointed to a lower incidence of HT with the C than with
the A allele, we have operationally defined the C allele
carriers as the reference group for our analysis. All statis-
tical tests were two-tailed and p-values < 0.05 were con-
sidered statistically significant. All statistical analyses
were done using SPSS 16.0 for Windows (SPSS Inc., Chi-
cago, IL, USA) or Prism version 4.0 (GraphPad, San
Diego, CA, USA). Post-hoc power calculations were per-
formed using the G*Power3 program http://www.psy-
cho.uni-duesseldorf.de/abteilungen/aap/gpower3/.
Results
Basic and genetic characteristics of the study population
The mean age of the study population (42.1% Blacks,
36.3% Whites, and 21.5% South Asians) was 45.4 ± 6.7
years with 41.6% being male. The BMI was 27.3 ± 5.2 kg/
m2. Mean SBP, DBP and MAP were 126.3 ± 19.7 mmHg,
82.0 ± 11.6 mmHg and 96.8 ± 13.8 mmHg, respectively,
with 15.6% of all subjects reporting use of antihyperten-
sive medication. According to our categorical definition
451 subjects (32.7%) were hypertensive. The genotype
prevalences are shown in Table 1. AGT T and AGTR1 A
represented the major alleles, whereas ACE D and I were
similarly prevalent. ACE I/D and AGTR1 A1166C poly-
morphisms were in Hardy-Weinberg equilibrium,
whereas the AGT M235T SNP was not.
Genotype association with HT
While the prevalence of HT did not differ significantly
between carriers of the AGT or ACE alleles, a signifi-
cantly higher HT prevalence was found in A allele carri-
ers of the AGTR1 (33.6% vs. 27.1%; Table 1). Accordingly,
FRPs containing the A allele of the AGTR1 also were
associated with a higher prevalence of HT, whereas the
FRP composed of alleles from AGT and ACE was not sig-
nificantly associated with HT (Table 1). Post-hoc calcula-
tions showed that the power to detect a group difference
in the prevalence of HT based on genotype was >0.6 for
the AGT or AGTR1 polymorphisms in isolation and in
combination. Given that the prevalence of HT was simi-
lar with both ACE alleles, the power for detecting a dif-
ference between them was low (<0.2). Accordingly, the
triple combination had a power of 0.482 to detect a group
difference.
Genotype association with blood pressure
Linear regression models using gender, ethnicity, age,
BMI and concomitant antihypertensive medication as
covariates did not detect statistically significant or clini-
cally relevant associations of AGT or ACE alleles with
SBP, DBP or MAP (Table 2). Consequently, the FRP com-
bining AGT and ACE alleles was also not associated with
blood pressure differences. While the A allele of the
AGTR1 was consistently associated with a numerically
higher SBP, DBP and MAP and even showed an apparent
gene dose-response, these differences did not reach sta-
tistical significance for any of the three blood pressure
measurements (Table 2). FRPs including the A allele of
the AGTR1 were also associated with higher SBP , DBP
and MAP; while these associations reached statistical sig-
nificance in several cases, they exhibited smaller effect
sizes than the A allele in isolation (Table 2).
Discussion
As AGT, ACE and AGTR1 act in concert, it has been pro-
posed that combinations of polymorphisms in the corre-
sponding three genes may exhibit stronger/more
consistent associations with phenotypes related to renal
function than those in each of the three genes studied in
isolation [17,18]. The present analysis was designed to
test this concept for a different phenotype, i.e. HT. How-
ever, our data do not support the idea that the FRP con-
cept can be extended to the high blood pressure
phenotype.Hahntow et al. BMC Cardiovascular Disorders 2010, 10:23
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Table 1: Prevalence of alleles and FRPs.
Genotype Number of 
alleles/FRPs
% prevalence 
of allele/FRP
Number of subjects 
with allele/FRP and HT
% prevalence of HT in 
group with allele/FRP
AGT
M 954 36.5 287 30.1
T 1662 63.5 561 33.9 (0.0512)
ACE
D 1352 51.3 451 33.5
I 1284 48.7 411 32.1 (0.4630)
AGTR1
C 402 15.4 109 27.1
A 2208 84.6 739 33.6 (0.0126)
AGT/ACE combination
M/I 385 12.9 107 30.1
T/D 764 27.7 270 35.3 (0.0560)
AGT/AGTR1 combination
M/C 294 10.7 83 28.2
T/A 1590 57.7 548 34.5 (0.0372)
ACE/AGTR1 combination
I/C 298 10.8 79 26.5
D/A 1253 45.4 420 33.5 (0.0227)
AGT/ACE/AGTR1 combination
M/I/C 203 7.4 56 27.6
T/D/A 803 29.1 279 34.7 (0.0555)
Data are absolute numbers of alleles (2 alleles per person and 2 FRPs per person) and their relative prevalence in %. P-values from Fisher's 
exact test vs. the reference genotype (M, I and C alleles, respectively) for the % prevalence of HT are given in parentheses. Note that two 
alleles/FRPs were identified per subject.Hahntow et al. BMC Cardiovascular Disorders 2010, 10:23
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Table 2: Difference in systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial pressure (MAP) 
associated with genotype.
SBP DBP MAP
AGT polymorphism
MM Reference group
MT -0.0 (-4.2; 4.2) -0.6 (-3.1; 1.9) -0.4 (-3.3; 2.5)
TT 2.4 (-1.9; 6.7) 0.8 (-1.8; 3.4) 1.3 (-1.7; 4.3)
ACE polymorphism
II Reference group
ID -0.9 (-3.8; 1.8) 0.6 (-1.1; 2.2) 0.1 (-1.9; 1.9)
DD 0.2 (-3.1; 3.5) 0.5 (-1.5; 2.4) 0.4 (-1.9; 2.7)
AGTR1polymorphism
CC Reference group
CA 5.7 (-3.9; 15.4) 2.4 (-3.4; 8.1) 3.5 (-3.2; 10.2)
AA 8.2 (-1.3; 17.7) 4.2 (-1.5; 9.8) 5.5 (-1.1; 12.1)
Combined AGT/ACE polymorphism
M/I Reference group
T/D 0.1 (-3.1; 3.4) 0.6 (-1.3; 2.5) 0.4 (-1.8; 2.7)
Combined AGT/AGTR1polymorphism
M/C Reference group
T/A 2.3 (-0.1; 4.6) 1.3 (-0.1; 2.8) 1.6 (-0.0; 3.3)
Combined ACE/AGTR1polymorphism
I/C Reference group
D/A 2.1 (-0.1; 4.3) 1.4 (0.1; 2.7) 1.6 (0.1; 3.2)
Combined AGT/ACE/AGTR1polymorphism
M/I/C Reference group
T/D/A 2.7 (-0.1; 5.4) 1.7 (0.1; 3.3) 2.0 (0.1; 3.9)
Data are shown as differences relative to the respective reference group expressed in mm Hg (95% confidence intervals) adjusted for age, 
gender, body mass index, ethnicity and concomitant antihypertensive medication. Note that confidence intervals excluding 1 are statistically 
equivalent to a p < 0.05.Hahntow et al. BMC Cardiovascular Disorders 2010, 10:23
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Critique of methods
Our analysis originates from a population-based sample
rather than a case-control design. This implies that only a
fraction of all participants were hypertensive and that a
fraction of the HT subjects were currently receiving anti-
hypertensive treatment. A detailed description of this
population has been presented previously [20-23].
While the PHASE program should also be suitable for
FRP analysis on mathematical grounds, it should be
pointed out that it was neither designed nor validated for
such analysis.
The detection of genotype-phenotype associations may
be complicated by various factors including ethnicity but
despite a large number of previous studies there is no
consistent evidence for ethnicity-dependent associations
of RAAS component polymorphisms with HT [5,11]. As
some ethnic groups were too small to allow analysis of
multiple loci, we have used the entire database but
included ethnicity as a co-explanatory variable to be on
the safe side. Ethnic differences in HT prevalence are
unlikely to have contributed to our analysis as this was
the target phenotype. Nevertheless, we cannot exclude
that a genotype may only manifest phenotypically in the
context of a specific ethnicity, and it also has to be consid-
ered that polymorphisms may display an ethnicity-
dependent prevalence [28,29].
To increase the robustness of our analysis [23,30], we
have concomitantly looked at two definitions of high
blood pressure phenotype, i.e. the presence of HT (cate-
gorical variable) and measured blood pressure (continu-
ous variable). For the latter, SBP, DBP and MAP were
used as target variables in order to further increase the
robustness of the analysis. Our use of the categorical vari-
able HT is in line with most previous studies but this is
less straightforward than it may appear because factors
such as age or obesity may confound the qualitative diag-
nosis of HT. Moreover, categorical variables tend to yield
less statistical power than continuous variables. There-
fore, we have concomitantly done all analyses based upon
the linear variables of SBP , DBP and MAP . Possible con-
founding factors such as age, gender, ethnicity, BMI and
concomitant antihypertensive medication were
a c c o u n t e d  f o r  b y  u s i n g  t h e m  a s  c o v a r i a t e s  i n  m u l t i p l e
regression models. Among these potential confounders,
concomitant antihypertensive medications is most diffi-
cult to handle in a population-based settings as standard-
ized pre-treatment blood pressure measurements
typically are not available. Restriction of the analysis to
control and non-treated hypertensive subjects was not
done for two reasons. Firstly, this would introduce bias
into the analysis which negates the advantages of a popu-
lation-based sample. Secondly, as about half of our hyper-
tensive subjects were on treatment (not atypical for a
population-based sample), their elimination from the
analysis would yield a too small group size for a meaning-
ful FRP analysis. Our previous work has shown that the
inclusion of concomitant medication as a covariate prob-
ably is, at least in this setting/situation, the most robust
way of handling this confounder [23].
Single gene polymorphisms
In our data set the M235T SNP in the AGT gene or the
ID polymorphism in the ACE gene did not significantly
associate with the blood pressure/hypertension pheno-
type. This is in line with the overall picture emerging
from many previous studies looking at these polymor-
phisms [5] or the genome-wide studies [12-15]. While the
AGT polymorphism in our data set did not exhibit
Hardy-Weinberg equilibrium, this does not affect the
overall picture that neither of these two polymorphisms
in isolation has a major role for blood pressure despite
their proven effect on the function of the RAAS. On the
other hand, the A allele of the A1166C SNP within the
AGTR1 gene was associated with a higher blood pressure
in our analysis. While a large number of studies on this
polymorphism did not reveal a major association with
blood pressure, if anything the C allele of this SNP had
been associated with higher blood pressure/hypertension
[5,11]. Given the overall lack of association, the occur-
rence of a study with the A allele showing an association
actually was not unexpected if indeed this locus has no
major impact on the blood pressure/hypertension pheno-
type as suggested by the genome-wide studies [12-15].
Single gene polymorphism vs. FRP associations with high 
blood pressure phenotypes
The main question of our analysis was whether the use of
FRPs allows detection of stronger and/or more consistent
detection of genotype/phenotype associations. With
regard to the categorical variable HT, FRPs were only
a s s oc i a t e d  i f  t h ey  i n c l u d e d  t h e  A  a l l e l e  o f  t h e  A G T R 1
gene. In these cases the prevalence of HT was rather sim-
ilar in FRPs containing the A allele as compared to A
allele carriers studied irrespective of their genotype for
the two other genes. A more complex situation was found
for the continuous phenotypic variables SBP, DBP and
MAP. For these three variables the use of FRPs yielded
statistical significance of genotype/phenotype associa-
tions in some cases where that was not found for the A
allele studied in isolation. On the other hand, apparent
effect sizes of the A allele were smaller when viewed in
the context of FRPs than when looking at the A allele in
isolation. Reaching statistical significance despite smaller
group and smaller effect sizes indicates that the use of
FRPs has yielded more consistent subpopulations with
smaller intra-group variance.Hahntow et al. BMC Cardiovascular Disorders 2010, 10:23
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Conclusions
At least for the high blood pressure phenotype, our data
do not support the previously proposed concept that
FRPs yield stronger genotype/phenotype associations
than individual polymorphisms of components of the
RAAS. However, they may yield more homogenous
patient groups, a possibility to be confirmed in future
studies in independent populations. FRPs containing not
only genes within the RAAS but also those of effectors of
the RAAS, e.g. those involved in sodium and water han-
dling, may also be worthwhile exploring. However, a
more in-depth analysis of haplotypes within single genes
and or the search for rare mutants with severe conse-
quences may be a more promising approach.
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